CoChat

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

Rolleman, Edgar, Valkema, Roelf, de Jong, Marion, Kooij, Peter, Krenning, Eric · 2003 · European Journal of Nuclear Medicine and Molecular Imaging

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Abstract

As scintigraphy with [(111)In-DTPA(0)]octreotide has become a standard technique in analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours, a logical next step is peptide receptor radionuclide therapy (PRRT). Initial studies on PRRT were performed with high doses of [(111)In-DTPA(0)]octreotide, and recently other radionuclides coupled to other somatostatin analogues have been used for this purpose. However, the dose delivered to the kidney is a major dose-limiting factor. Amino acid solutions have previously been used to reduce renal uptake of radioactivity, but these solutions have some disadvantages, i.e. their hyperosmolarity and their propensity to cause vomiting and metabolic changes. In this study we tested various amino acid solutions in patients receiving [(111)In-DTPA(0)]octreotide PRRT in order to assess their safety and their capacity to inhibit the renal uptake of radioactivity. Patients served as their own non-infused control. Renal radioactivity at 24 h following the injection of [(111)In-DTPA(0)]octreotide was inhibited by (1) a commercially available amino acid solution (AA) (21%+/-14%, P<0.02), (2) by 25 g (17%+/-9%, P<0.04), 50 g (15%+/-13%, P<0.04) or 75 g of lysine (44%+/-11%, P<0.001) and (3) by a combination of 25 g of lysine plus 25 g of arginine (LysArg) (33%+/-23%, P<0.01). Fluid infusion alone (500, 1,000 or 2,000 ml of saline/glucose) did not change renal uptake of radioactivity. In patients studied with 75 g of lys…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00259-002-0982-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 347

Metadata

Authors
Rolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E.
Affiliations
Erasmus MC (NL)
Corresponding author
Valkema, Roelf
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2003-01-01
Volume
30
Issue
1
Pages
9-15
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2027511464
Cited by
321
References
24
Citations by year
2026: 8 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 27 · 2020: 19 · 2019: 11 · 2018: 15 · 2017: 14 · 2016: 12 · 2015: 9 · 2014: 17 · 2013: 14 · 2012: 17
FWCI
11.78
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
lysine, L-arginine, amino acid infusion, peptide receptor radionuclide therapy, somatostatin receptors, neuroendocrine tumors, indium-111 octreotide, serum potassium, hyperkalemia, fluid infusion, safety and tolerability
MeSH terms
Arginine, Pentetic Acid, Female, Humans, Hyperkalemia, Infusions, Intravenous, Kidney, Lysine, Radionuclide Imaging, Vomiting, Octreotide, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. https://app.cochat.ai/papers/10.1007/s00259-002-0982-3
The paper
Rolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E. (2003). Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-002-0982-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.